Latest news with #PureHealthHoldingPJSC
Al Etihad
01-05-2025
- Business
- Al Etihad
PureHealth reports Dh505 million net profit, Dh1.1 billion EBITDA for Q1 2025
1 May 2025 17:59 ABU DHABI (ALETIHAD)PureHealth Holding PJSC (PureHealth or the Group) (ADX Symbol: PUREHEALTH) announced on Thursday its financial results for the three-month period ended March 31, group's revenue increased 8% year-on-year to Dh6.6 billion, driven by growth across all of PureHealth's segments. EBITDA grew 5% year-on-year to Dh1.1 billion, and net profit grew 3% year-on-year to Dh505 million in Q1 Al Maazmi, Chairman of PureHealth, said, "PureHealth's strong Q1 2025 results underscore the strength of our integrated healthcare model and the resilience of our long-term strategy. We are redefining healthcare delivery, by combining operational excellence with cutting-edge innovation, to raise the standard of care across the region and beyond. As we continue to expand our global presence and invest in future-ready medical capabilities, our focus remains clear—delivering superior patient care, creating sustainable value for our shareholders, and making a meaningful, long-term impact on the health and well-being of the communities we serve." Shaista Asif, Group Chief Executive Officer at PureHealth, commented, "PureHealth's first quarter results reflect the solid growth witnessed across all core segments. The Group's results for the period came on the back of strong patient volume increases across our hospital network, both locally and internationally, and continued momentum in our insurance division with high renewal rates and expansion into new markets. Our strong operational execution, transformations of the assets, and the synergies between the entities are delivering tangible results, and strengthening the foundation for future growth. As we look ahead, PureHealth is well-positioned to continue expanding our reach, deepening our platform capabilities, and advancing specialised care to meet the evolving needs of the healthcare sector both in the UAE and internationally."
Associated Press
01-05-2025
- Business
- Associated Press
PureHealth Reports USD 137.6 Million Net Profit and USD 308.5 Million EBITDA for First Quarter 2025
ABU DHABI, UAE, May 1, 2025 /PRNewswire/ -- PureHealth Holding PJSC ('PureHealth' or 'the Group') (ADX Symbol: PUREHEALTH), the largest healthcare group in the Middle East, today announced its financial results for the three-month period ended 31 March 2025. The Group's revenue increased 8% year-on-year to USD 1.8 billion driven by growth across all of PureHealth's segments. EBITDA grew 5% year-on-year to USD 308.5 million and net profit grew 3% year-on-year to USD 137.6 million in Q1-2025. H.E Kamal Al Maazmi, Chairman of PureHealth, said: 'PureHealth's strong Q1-2025 results underscore the strength of our integrated healthcare model and the resilience of our long-term strategy. We are redefining healthcare delivery by combining operational excellence with cutting-edge innovation to raise the standard of care across the region and beyond. As we continue to expand our global presence and invest in future-ready medical capabilities, our focus remains clear—delivering superior patient care, creating sustainable value for our shareholders, and making a meaningful, long-term impact on the health and well-being of the communities we serve.' Shaista Asif, Group Chief Executive Officer at PureHealth, commented, 'PureHealth's first quarter results reflect the solid growth witnessed across all core segments. The Group's results for the period came on the back of strong patient volume increases across our hospital network, both locally and internationally, and continued momentum in our insurance division with high renewal rates and expansion into new markets. Our strong operational execution, transformations of the assets, and the synergies between the entities are delivering tangible results, and strengthening the foundation for future growth. As we look ahead, PureHealth is well-positioned to continue expanding our reach, deepening our platform capabilities, and advancing specialised care to meet the evolving needs of the healthcare sector both in the UAE and internationally.' Financial & Operational Highlights The Group's positive performance was driven by growth across all segments in Q1-2025. The Hospital segment remained the largest contributor to the Group's top-line at 59%, with revenue growing 3% year-on-year to USD 1.4 billion in Q1-2025. The segment's performance was supported by sustained momentum in patient volumes and strategic investments in expanding both service breadth and geographic reach across PureHealth's UAE and UK assets. On this front, PureHealth recorded over 2.5 million patient interactions during the quarter across its UAE and UK assets, up 9% year-on-year. Additionally, inpatient visits rose by 4% year-on-year to approximately 53,000, while outpatient volumes grew by 9% year-on-year to reach 2.2 million and hospital bed capacity increased 2% year-on-year to 5,500 beds in Q1-2025. The Insurance segment generated USD 507.4 million in revenue, up 19% year-on-year in Q1-2025. This growth was supported by a 15% year-on-year increase in Gross Written Premiums, reflecting strong renewal rates and expansion into underpenetrated markets. New product launches, as well as a global partnership with AXA for international private medical insurance, helped diversify the portfolio and enhance customer value. Overall, active membership grew to 3.2 million, while over 13.9 million claims were processed in Q1-2025. The Procurement segment generated revenues of USD 320.6 million in the first quarter, representing a 11% year-on-year increase compared to the previous year. Growth was largely driven by strengthened partnerships with suppliers, an expanding client base across the UAE and GCC, and an increased share of high-tech medical equipment and specialty pharmaceuticals in the Group's procurement mix. Revenue from Diagnostic Services increased 14% year-on-year to USD 71.0 million, driven by a 16% year-on-year increase in testing volumes in Q1-2025. Moreover, further supporting the segment's performance was the integration of Sheikh Shakhbout Medical City (SSMC) into the PureLab network, which contributed over 700,000 additional test volumes. In addition, SEHA clinics continued to scale their laboratory operations, further driving utilisation and strengthening the segment's performance. The Technology Services segment reported revenue growth of 132% year-on-year to USD 41.4 million in Q1-2025. This was led by PureCS, PureHealth's dedicated technology company, which made substantial progress in deploying clinical and operational technology across solutions during the period. Strategic Developments Outlook Looking ahead, PureHealth remains firmly committed to building a resilient, technology-driven global healthcare platform. By embedding digital intelligence across its integrated ecosystem, PureHealth is redefining healthcare delivery and driving sustainable value. Moreover, the Group is advancing organic growth through service expansion, clinical innovation, and capacity building, while scaling internationally through targeted acquisitions. On this front, PureHealth will accelerate its global expansion strategy through the integration of new assets, including the addition of Hellenic Healthcare Group (HHG) in Europe to the Group's portfolio. Moreover, with a fortified balance sheet following the early repayment of USD 502.3 million in debt during Q1-2025, PureHealth is well-positioned to reinvest in high-growth opportunities and deliver sustainable value for its stakeholders. Photo - View original content to download multimedia: SOURCE Pure Health Holding PJSC
Zawya
01-05-2025
- Business
- Zawya
PureHealth reports AED505mln net profit and AED1.1bln EBITDA for first quarter 2025
Abu Dhabi – PureHealth Holding PJSC ('PureHealth' or 'the Group') (ADX Symbol: PUREHEALTH), the largest healthcare group in the Middle East, today announced its financial results for the three-month period ended 31 March 2025. The Group's revenue increased 8% year-on-year to AED 6.6 billion driven by growth across all of PureHealth's segments. EBITDA grew 5% year-on-year to AED 1.1 billion and net profit grew 3% year-on-year to AED 505 million in Q1-2025. H.E Kamal Al Maazmi, Chairman of PureHealth, said: 'PureHealth's strong Q1 2025 results underscore the strength of our integrated healthcare model and the resilience of our long-term strategy. We are redefining healthcare delivery by combining operational excellence with cutting-edge innovation to raise the standard of care across the region and beyond. As we continue to expand our global presence and invest in future-ready medical capabilities, our focus remains clear—delivering superior patient care, creating sustainable value for our shareholders, and making a meaningful, long-term impact on the health and well-being of the communities we serve.' Shaista Asif, Group Chief Executive Officer at PureHealth, commented, 'PureHealth's first quarter results reflect the solid growth witnessed across all core segments. The Group's results for the period came on the back of strong patient volume increases across our hospital network, both locally and internationally, and continued momentum in our insurance division with high renewal rates and expansion into new markets. Our strong operational execution, transformations of the assets, and the synergies between the entities are delivering tangible results, and strengthening the foundation for future growth. As we look ahead, PureHealth is well-positioned to continue expanding our reach, deepening our platform capabilities, and advancing specialised care to meet the evolving needs of the healthcare sector both in the UAE and internationally.' Financial & Operational Highlights The Group's positive performance was driven by growth across all segments in Q1-2025. The Hospital segment remained the largest contributor to the Group's top-line at 59%, with revenue growing 3% year-on-year to AED 5.0 billion in Q1 2025. The segment's performance was supported by sustained momentum in patient volumes and strategic investments in expanding both service breadth and geographic reach across PureHealth's UAE and UK assets. On this front, PureHealth recorded over 2.5 million patient interactions during the quarter across its UAE and UK assets, up 9% year-on-year. Additionally, inpatient visits rose by 4% year-on-year to approximately 53,000, while outpatient volumes grew by 9% year-on-year to reach 2.2 million and hospital bed capacity increased 2% year-on-year to 5,500 beds in Q1-2025. The Insurance segment generated AED 1.86 billion in revenue, up 19% year-on-year in Q1-2025. This growth was supported by a 15% year-on-year increase in Gross Written Premiums, reflecting strong renewal rates and expansion into underpenetrated markets. New product launches, as well as a global partnership with AXA for international private medical insurance, helped diversify the portfolio and enhance customer value. Overall, active membership grew to 3.2 million, while over 13.9 million claims were processed in Q1-2025. The Procurement segment generated revenues of AED 1.2 billion in the first quarter, representing a 11% year-on-year increase compared to the previous year. Growth was largely driven by strengthened partnerships with suppliers, an expanding client base across the UAE and GCC, and an increased share of high-tech medical equipment and specialty pharmaceuticals in the Group's procurement mix. Revenue from Diagnostic Services increased 14% year-on-year to AED 261 million, driven by a 16% year-on-year increase in testing volumes in Q1-2025. Moreover, further supporting the segment's performance was the integration of Sheikh Shakhbout Medical City (SSMC) into the PureLab network, which contributed over 700,000 additional test volumes. In addition, SEHA clinics continued to scale their laboratory operations, further driving utilisation and strengthening the segment's performance. The Technology Services segment reported revenue growth of 132% year-on-year to AED 152 million in Q1-2025. This was led by PureCS, PureHealth's dedicated technology company, which made substantial progress in deploying clinical and operational technology across solutions during the period. Strategic Developments Following its Annual General Assembly, PureHealth announced a dividend of AED 343 million for FY 2024, its first distribution post-listing on the ADX which represented a 20% payout ratio. In the UAE, PureHealth continued to strengthen its leadership in healthcare delivery. SEHA advanced its transplant programmes, expanded mental health services, opened new outpatient clinics, and onboarded over 150 specialist physicians to support specialised care. Additionally, SSMC reinforced its cardiac and specialty care footprint through the launch of advanced diagnostic centres, cutting-edge procedures, and new specialty clinics focused on women's and adolescent mental health. Internationally, Circle Health Group in the UK further established itself as an innovation leader by securing the largest European order of surgical robots, expanding outpatient services with new centres in Cheshire, Inverness, and Glasgow, enhancing physiotherapy capabilities, and advancing oncology care through in-house monoclonal antibody preparation. Daman launched "Amanak," a new insurance product tailored for employees of small and medium businesses in the Northern Emirates. It also entered into a global partnership with AXA to offer International Private Medical Insurance (IPMI) products, expanding its international reach. In parallel, Daman provided facultative reinsurance offerings, supported by its strong financial position and solid solvency metrics. The company also accelerated initiatives to enhance customer experience, deepen collaboration with government entities, and deploy digital solutions to drive greater operational efficiency. Our Diagnostics vertical, PureLab, launched the Abu Dhabi Public Health Centre Surveillance Lab in February 2025, specialising in molecular and genomics testing to strengthen public health capabilities. Additionally, PureLab signed an MoU with ExpressMed Diagnostics & Research Bahrain to expand its reach and cater to referral volumes from outside the UAE. The Group's procurement arm, Rafed, managed the Nationwide Immunisation Programme on behalf of the UAE Government. Looking ahead, PureHealth remains firmly committed to building a resilient, technology-driven global healthcare platform. By embedding digital intelligence across its integrated ecosystem, PureHealth is redefining healthcare delivery and driving sustainable value. Moreover, the Group is advancing organic growth through service expansion, clinical innovation, and capacity building, while scaling internationally through targeted acquisitions. On this front, PureHealth will accelerate its global expansion strategy through the integration of new assets, including the addition of Hellenic Healthcare Group (HHG) in Europe to the Group's portfolio. Moreover, with a fortified balance sheet following the early repayment of AED 1.85 billion in debt during Q1 2025, PureHealth is well-positioned to reinvest in high-growth opportunities and deliver sustainable value for its stakeholders. About PureHealth: PureHealth is the largest healthcare group in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 110+ hospitals, 316+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more, its groundbreaking innovations are at the forefront of healthcare as the company is on a mission to unlock time for humankind. By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth's network comprises: SEHA – One of the largest healthcare networks of hospitals and clinics in the UAE SEHA CLINICS - Delivering comprehensive community-based healthcare services Sheikh Shakhbout Medical City (SSMC) – The UAE's largest healthcare complex, delivering integrated complex care The Medical Office – Overseeing Sheikh Khalifa Hospitals and healthcare facilities established under the initiatives of H.H. The President of the UAE Daman (The National Health Insurance Company) – The UAE's leading health insurer Rafed – The UAE's largest healthcare Group Purchasing Organisation PureLab – Managing and operating the largest network of laboratories in the region One Health – A network that provides end-to-end medical solutions to a base of over 300 healthcare service providers The Life Corner – Abu Dhabi's first holistic pharmacy, serving the health and wellness establishment Ardent Health Services – The fourth largest privately held acute care hospital operator in the US Circle Health Group – The largest independent operators of hospitals in the UK Hellenic Healthcare Group (HHG) - the largest private healthcare provider in Greece and Cyprus PureCS - A leading cloud and technology services provider, specialising in IT management and consulting solutions, cybersecurity, cloud services and AI information systems
Yahoo
20-03-2025
- Business
- Yahoo
Global Market Highlights 3 Stocks That May Be Trading Below Their Estimated Value
As global markets navigate a challenging landscape marked by easing U.S. inflation, ongoing trade policy uncertainties, and recession fears, investors are keenly observing the performance of major indices like the S&P 500 and Nasdaq Composite, which have recently faced consecutive weeks of negative returns. In this environment where economic indicators fluctuate and sentiment is cautious, identifying undervalued stocks can offer potential opportunities for investors seeking value. Name Current Price Fair Value (Est) Discount (Est) Guizhou Space Appliance (SZSE:002025) CN¥58.35 CN¥115.74 49.6% Storytel (OM:STORY B) SEK90.85 SEK180.37 49.6% Takara Bio (TSE:4974) ¥853.00 ¥1696.74 49.7% APAC Realty (SGX:CLN) SGD0.43 SGD0.85 49.6% JSHLtd (TSE:150A) ¥558.00 ¥1106.93 49.6% Nan Ya Printed Circuit Board (TWSE:8046) NT$132.00 NT$262.13 49.6% Sunny Optical Technology (Group) (SEHK:2382) HK$88.50 HK$175.51 49.6% Jiangsu Chuanzhiboke Education Technology (SZSE:003032) CN¥8.53 CN¥16.91 49.6% Shenzhen Anche Technologies (SZSE:300572) CN¥18.60 CN¥37.18 50% Doosan Fuel Cell (KOSE:A336260) ₩15880.00 ₩31544.03 49.7% Click here to see the full list of 505 stocks from our Undervalued Global Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: Pure Health Holding PJSC operates in the healthcare services sector in the United Arab Emirates, with a market capitalization of approximately AED32.67 billion. Operations: The company generates revenue through various segments including Diagnostic Services (AED1.06 billion), Technology and Others (AED468.57 million), Health Insurance Services (AED6.84 billion), Hospital and Other Healthcare Related Services (AED19.65 billion), and Procurement and Supply of Medical Related Products (AED5.20 billion). Estimated Discount To Fair Value: 10.3% Pure Health Holding PJSC is trading at AED2.94, slightly below its fair value of AED3.28, suggesting it may be undervalued based on cash flows. Despite a modest revenue growth forecast of 9% annually, earnings are expected to grow significantly at 20.95% per year, outpacing the AE market's average. Recent earnings showed substantial improvement with net income rising to AED 1.71 billion from AED 964.66 million last year, indicating strong profitability momentum. Insights from our recent growth report point to a promising forecast for Pure Health Holding PJSC's business outlook. Click to explore a detailed breakdown of our findings in Pure Health Holding PJSC's balance sheet health report. Overview: Taiwan Semiconductor Manufacturing Company Limited, with a market cap of NT$24.69 trillion, operates globally by manufacturing, packaging, testing, and selling integrated circuits and other semiconductor devices. Operations: The company's revenue segment primarily consists of its Foundry operations, which generated NT$2.89 billion. Estimated Discount To Fair Value: 40.9% Taiwan Semiconductor Manufacturing is trading at NT$982, significantly below its fair value estimate of NT$1662.74, highlighting potential undervaluation based on cash flows. The company's earnings are projected to grow at 16.6% annually, surpassing the Taiwan market average growth rate of 15.7%. Recent revenue reports show a robust increase with February's net revenue reaching TWD 260 billion compared to TWD 181.65 billion last year, supporting strong cash flow generation capabilities. According our earnings growth report, there's an indication that Taiwan Semiconductor Manufacturing might be ready to expand. Click here to discover the nuances of Taiwan Semiconductor Manufacturing with our detailed financial health report. Overview: Micro-Star International Co., Ltd. is a company that manufactures and sells motherboards, interface cards, notebook computers, and other electronic products globally, with a market cap of NT$144.47 billion. Operations: The company's revenue from the Computer and Peripherals segment amounts to NT$197.83 billion. Estimated Discount To Fair Value: 38.4% Micro-Star International is trading at NT$171.5, significantly below its estimated fair value of NT$278.44, suggesting undervaluation based on cash flows. Despite a decrease in net income to TWD 6.79 billion from TWD 7.53 billion the previous year, the company's earnings are expected to grow significantly at 30.69% annually, outpacing both revenue growth and the Taiwan market average. However, its dividend yield of 2.92% is not fully supported by free cash flows. Upon reviewing our latest growth report, Micro-Star International's projected financial performance appears quite optimistic. Take a closer look at Micro-Star International's balance sheet health here in our report. Discover the full array of 505 Undervalued Global Stocks Based On Cash Flows right here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ADX:PUREHEALTH TWSE:2330 and TWSE:2377. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Zawya
18-03-2025
- Business
- Zawya
PureHealth proposes AED 343mln dividend following strong first year post-listing
Shareholders to review the dividend proposal and financial position at the AGM on 9 April Abu Dhabi – PureHealth Holding PJSC ('PureHealth' or 'the Group') (ADX Symbol: PUREHEALTH), the largest healthcare group in the Middle East, has announced a proposal for its first-ever dividend distribution since listing on the Abu Dhabi Securities Exchange (ADX) in December 2023. The Board of Directors has recommended a total dividend of AED 343 million (AED 3.09 fils per share) for the 2024 financial year, representing 20% of the Group's net profit. The proposal is set for shareholder approval at the Annual General Meeting (AGM) on 9 April 2025. This follows the completion of PureHealth's first full financial year as a publicly listed company, reflecting the Group's strong performance and financial resilience. The proposed dividend highlights the strength of PureHealth's balance sheet, its ability to generate returns for shareholders, and its capacity to grow the business while maintaining a robust capital position. The remainder of the Group's profits will be retained, providing financial flexibility to support future growth plans and potential global expansion opportunities. PureHealth concluded the 2024 financial year with exceptionally strong financial performance, underscored by revenues of AED 25.8 billion, EBITDA of AED 4.1 billion, and a net profit of AED 1.7 billion. Bolstered by a substantial cash position of AED 11.9 billion and maintaining an impressively low leverage ratio of approximately 0.1x, the Group's balance sheet provides ample strategic flexibility. Operating within a resilient sector, PureHealth's robust financial footing positions it comfortably to pursue its ambitious growth and acquisition agenda, further solidifying its status as a prominent healthcare group in the region and beyond. As part of its continued growth, PureHealth recently acquired a 60% stake in Hellenic Healthcare Group from the global private equity firm CVC, which will remain as a minority partner alongside PureHealth within the acquired entity. The Group remains focused on expanding its presence and capabilities to drive excellence across its global operations. The proposed dividend marks a key milestone in PureHealth's journey as a publicly listed entity, reflecting its strong financial standing and commitment to delivering shareholder value. Pending approval at the AGM, the dividend distribution will demonstrate the Group's ability to generate returns and create value for shareholders.
